Epidemiology of lung cancer

KC Thandra, A Barsouk, K Saginala, JS Aluru… - Contemporary …, 2021 - termedia.pl
Lung cancer is the leading cause of global cancer incidence and mortality, accounting for an
estimated 2 million diagnoses and 1.8 million deaths. Neoplasms of the lungs are the …

Desired turbulence? Gut‐lung axis, immunity, and lung cancer

R Bingula, M Filaire, N Radosevic-Robin… - Journal of …, 2017 - Wiley Online Library
The microbiota includes different microorganisms consisting of bacteria, fungi, viruses, and
protozoa distributed over many human body surfaces including the skin, vagina, gut, and …

Racial/ethnic disparities in genomic sequencing

DE Spratt, T Chan, L Waldron, C Speers… - JAMA …, 2016 - jamanetwork.com
Importance Although poorly understood, there is heterogeneity in the molecular biology of
cancer across race and ethnicities. The representation of racial minorities in large genomic …

[PDF][PDF] Multiple primary lung cancer: a literature review

AM Romaszko, A Doboszyńska - Adv Clin Exp Med, 2018 - pdfs.semanticscholar.org
Nowadays, lung cancer is a leading cause of death in both men and women worldwide.
There is no clear explanation for its mortality rate. However, it is already known that genetic …

Tumor microenvironment differences between primary tumor and brain metastases

B Cacho-Díaz, DR García-Botello… - Journal of Translational …, 2020 - Springer
The present review aimed to discuss contemporary scientific literature involving differences
between the tumor microenvironment (TME) in melanoma, lung cancer, and breast cancer in …

[PDF][PDF] Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins

MH Widyananda, SK Pratama… - J Pharm …, 2021 - researchgate.net
Abstract Resumen Context: Lung cancer is a type of cancer that causes the most deaths
worldwide. The most common type of lung cancer is non-small cell lung cancer (NSCLC) …

The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer

J Zhou, WY Zhao, X Ma, RJ Ju, XY Li, N Li, MG Sun… - Biomaterials, 2013 - Elsevier
Lung cancer is the leading cause of cancer-related death in humans and the multidrug
resistance (MDR) is the major obstacle to successful chemotherapy of lung cancer. In this …

[HTML][HTML] Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients

HC Hsu, TK Thiam, YJ Lu, CY Yeh, WS Tsai, JF You… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS
exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers …

Racial and ethnic differences in the epidemiology and genomics of lung cancer

MB Schabath, WD Cress, T Muñoz-Antonia - Cancer Control, 2016 - journals.sagepub.com
Background Lung cancer is the most common cancer in the world. In addition to the
geographical and sex-specific differences in the incidence, mortality, and survival rates of …

Novel targets, novel treatments: the changing landscape of non-small cell lung cancer

D de Jong, JP Das, H Ma, J Pailey Valiplackal… - Cancers, 2023 - mdpi.com
Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …